Tumor-treating Fields Plus Chemotherapy Versus Chemotherapy Alone for Glioblastoma at First Recurrence: a Post Hoc Analysis of the EF-14 Trial

Overview

Journal CNS Oncol

Specialty Oncology

Date 2017 Apr 13

PMID 28399638

Citations 32

Authors

Santosh Kesari

Zvi Ram

Affiliations

Soon will be listed here.

Abstract

Background: This post hoc analysis of the EF-14 trial (NCT00916409) of tumor-treating fields (TTFields) plus temozolomide versus temozolomide alone in newly diagnosed glioblastoma compared the efficacy of TTFields plus chemotherapy (physician's choice) versus chemotherapy alone after first recurrence.

Methods: Patients on TTFields plus temozolomide continued TTFields plus second-line chemotherapy after first recurrence. Some patients on temozolomide alone crossed over after approval of TTFields for recurrent GBM. The primary efficacy outcome was overall survival (OS).

Results: After disease progression, 131 patients received TTFields plus chemotherapy and 73 chemotherapy alone. Thirteen patients in the original temozolomide-alone group crossed over to receive TTFields plus chemotherapy after disease progression, resulting in 144 patients receiving TTFields plus chemotherapy and 60 chemotherapy alone. Median follow-up was 12.6 months. Bevacizumab, alone or with cytotoxic chemotherapy, was the most frequent treatment. Median OS in the TTFields plus chemotherapy group was significantly longer versus chemotherapy alone (11.8 vs 9.2 months; HR: 0.70; 95% CI, 0.48-1.00; p=0.049). TTFields showed a low toxicity safety profile, as previously reported, with no grade 3/4 device-related adverse events.

Conclusion: TTFields plus chemotherapy after first disease recurrence on TTFields plus temozolomide or temozolomide alone prolonged OS in patients in the EF-14 trial.

Citing Articles

Response Assessment in Long-Term Glioblastoma Survivors Using a Multiparametric MRI-Based Prediction Model.

de Godoy L, Rajan A, Banihashemi A, Patel T, Desai A, Bagley S Brain Sci. 2025; 15(2).

PMID: 40002479 PMC: 11852837. DOI: 10.3390/brainsci15020146.

Advancements and challenges in brain cancer therapeutics.

Bai F, Deng Y, Li L, Lv M, Razzokov J, Xu Q Exploration (Beijing). 2024; 4(6):20230177.

PMID: 39713205 PMC: 11655316. DOI: 10.1002/EXP.20230177.

Tumor Treating Fields (TTFields) Therapy and Lomustine Chemotherapy for the Treatment of Unresectable Progressive Glioblastoma.

Mergen E, Landrock S, Chizzali B Case Rep Oncol. 2024; 17(1):1056-1062.

PMID: 39474554 PMC: 11521457. DOI: 10.1159/000540669.

Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma.

Khagi S, Kotecha R, Gatson N, Jeyapalan S, Abdullah H, Avgeropoulos N Oncologist. 2024; 30(2).

PMID: 39401002 PMC: 11883162. DOI: 10.1093/oncolo/oyae227.

Efficacy of tumour-treating fields therapy in recurrent glioblastoma: A narrative review of current evidence.

Olatunji G, Aderinto N, Adefusi T, Kokori E, Akinmoju O, Yusuf I Medicine (Baltimore). 2023; 102(48):e36421.

PMID: 38050252 PMC: 10695547. DOI: 10.1097/MD.0000000000036421.

References

Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-66. DOI: 10.1016/S1470-2045(09)70025-7. View

Gilbert M, Dignam J, Armstrong T, Wefel J, Blumenthal D, Vogelbaum M . A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8):699-708. PMC: 4201043. DOI: 10.1056/NEJMoa1308573. View

Stupp R, Wong E, Kanner A, Steinberg D, Engelhard H, Heidecke V . NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012; 48(14):2192-202. DOI: 10.1016/j.ejca.2012.04.011. View

Kim E, Kim Y, Song H, Jeong Y, Lee J, Sung J . Biological effect of an alternating electric field on cell proliferation and synergistic antimitotic effect in combination with ionizing radiation. Oncotarget. 2016; 7(38):62267-62279. PMC: 5308725. DOI: 10.18632/oncotarget.11407. View

Kim E, Song H, Yoo S, Yoon M . Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis. Oncotarget. 2016; 7(40):65125-65136. PMC: 5323142. DOI: 10.18632/oncotarget.11372. View

Stupp R, Hegi M, Gorlia T, Erridge S, Perry J, Hong Y . Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 15(10):1100-8. DOI: 10.1016/S1470-2045(14)70379-1. View

Kirson E, Schneiderman R, Dbaly V, Tovarys F, Vymazal J, Itzhaki A . Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med Phys. 2009; 9:1. PMC: 2647898. DOI: 10.1186/1756-6649-9-1. View

Chen C, Ravelo A, Yu E, Dhanda R, Schnadig I . Clinical outcomes with bevacizumab-containing and non-bevacizumab-containing regimens in patients with recurrent glioblastoma from US community practices. J Neurooncol. 2015; 122(3):595-605. PMC: 4436682. DOI: 10.1007/s11060-015-1752-y. View

Ostrom Q, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C . CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro Oncol. 2015; 17 Suppl 4:iv1-iv62. PMC: 4623240. DOI: 10.1093/neuonc/nov189. View

10.

Gilbert M, Wang M, Aldape K, Stupp R, Hegi M, Jaeckle K . Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013; 31(32):4085-91. PMC: 3816958. DOI: 10.1200/JCO.2013.49.6968. View

11.

Macdonald D, Cascino T, Schold Jr S, Cairncross J . Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8(7):1277-80. DOI: 10.1200/JCO.1990.8.7.1277. View

12.

Chinot O, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R . Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8):709-22. DOI: 10.1056/NEJMoa1308345. View

13.

Gallego O . Nonsurgical treatment of recurrent glioblastoma. Curr Oncol. 2015; 22(4):e273-81. PMC: 4530825. DOI: 10.3747/co.22.2436. View

14.

Friedman H, Prados M, Wen P, Mikkelsen T, Schiff D, Abrey L . Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27(28):4733-40. DOI: 10.1200/JCO.2008.19.8721. View

15.

Mrugala M, Engelhard H, Tran D, Kew Y, Cavaliere R, Villano J . Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe). Semin Oncol. 2014; 41 Suppl 6:S4-S13. DOI: 10.1053/j.seminoncol.2014.09.010. View

16.

Santoni M, Scoccianti S, Lolli I, Fabrini M, Silvano G, Detti B . Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma. J Neurooncol. 2013; 113(3):397-401. PMC: 3684712. DOI: 10.1007/s11060-013-1125-3. View

17.

Stupp R, Taillibert S, Kanner A, Kesari S, Steinberg D, Toms S . Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA. 2015; 314(23):2535-43. DOI: 10.1001/jama.2015.16669. View

18.

Hottinger A, Pacheco P, Stupp R . Tumor treating fields: a novel treatment modality and its use in brain tumors. Neuro Oncol. 2016; 18(10):1338-49. PMC: 5035531. DOI: 10.1093/neuonc/now182. View

19.

. Prognostic factors for high-grade malignant glioma: development of a prognostic index. A Report of the Medical Research Council Brain Tumour Working Party. J Neurooncol. 1990; 9(1):47-55. DOI: 10.1007/BF00167068. View

20.

Westphal M, Heese O, Steinbach J, Schnell O, Schackert G, Mehdorn M . A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. Eur J Cancer. 2015; 51(4):522-532. DOI: 10.1016/j.ejca.2014.12.019. View